Canlyniadau Chwilio - F. Stephen Hodi

Mireinio'r Canlyniadau
  1. 1
    Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

    Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade gan Elizabeth Buchbinder, F. Stephen Hodi

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis

    Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis gan Le Min, F. Stephen Hodi

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma

    Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma gan Jason J. Luke, F. Stephen Hodi

    Cyhoeddwyd 2013
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity

    Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity gan Masahisa Jinushi, F. Stephen Hodi, Glenn Dranoff

    Cyhoeddwyd 2006
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Imaging of Cancer Immunotherapy: Current Approaches and Future Directions

    Imaging of Cancer Immunotherapy: Current Approaches and Future Directions gan Mizuki Nishino, Hiroto Hatabu, F. Stephen Hodi

    Cyhoeddwyd 2018
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Mutation-driven drug development in melanoma

    Mutation-driven drug development in melanoma gan Keith T. Flaherty, F. Stephen Hodi, Boris C. Bastian

    Cyhoeddwyd 2010
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

    Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial... gan Patrick A. Ott, F. Stephen Hodi, Elizabeth I. Buchbinder

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Ipilimumab and Its Toxicities: A Multidisciplinary Approach

    Ipilimumab and Its Toxicities: A Multidisciplinary Approach gan Leslie A. Fecher, Sanjiv S. Agarwala, F. Stephen Hodi, Jeffrey S. Weber

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Drug-Related Pneumonitis in the Era of Precision Cancer Therapy

    Drug-Related Pneumonitis in the Era of Precision Cancer Therapy gan Mizuki Nishino, Hiroto Hatabu, F. Stephen Hodi, Nikhil H. Ramaiya

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Monitoring immune-checkpoint blockade: response evaluation and biomarker development

    Monitoring immune-checkpoint blockade: response evaluation and biomarker development gan Mizuki Nishino, Nikhil H. Ramaiya, Hiroto Hatabu, F. Stephen Hodi

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

    Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome gan Mizuki Nishino, Anita Giobbie‐Hurder, Nikhil H. Ramaiya, F. Stephen Hodi

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

    Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment gan Mizuki Nishino, Sree Harsha Tirumani, Nikhil H. Ramaiya, F. Stephen Hodi

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma

    Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma gan Trevor E. Angell, Le Min, Tad J. Wieczorek, F. Stephen Hodi

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

    Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? gan Mizuki Nishino, Maria Gargano, Margaret Suda, Nikhil H. Ramaiya, F. Stephen Hodi

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

    Hepatotoxicity with Combination of Vemurafenib and Ipilimumab gan Antoni Ribas, F. Stephen Hodi, Margaret K. Callahan, Cyril Konto, Jedd D. Wolchok

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

    The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition gan Xiaofeng Jiang, Jun Zhou, Anita Giobbie‐Hurder, Jennifer A. Wargo, F. Stephen Hodi

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways

    Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways gan Xinqi Wu, Jingjing Li, Mei‐Jun Zhu, Jonathan A. Fletcher, F. Stephen Hodi

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

    Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer gan Mizuki Nishino, Anita Giobbie‐Hurder, Hiroto Hatabu, Nikhil H. Ramaiya, F. Stephen Hodi

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies

    Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies gan Meenal Datta, Lisa M. Coussens, Hiroyoshi Nishikawa, F. Stephen Hodi, Rakesh K. Jain

    Cyhoeddwyd 2019
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy

    Anti–PD-1–Related Pneumonitis during Cancer Immunotherapy gan Mizuki Nishino, Lynette M. Sholl, Hiroto Hatabu, Nikhil H. Ramaiya, F. Stephen Hodi

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: